- Home
- HGV vs NAMS Comparison
HGV vs NAMS Comparison
Compare HGV & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HGV | NAMS |
|---|---|---|
| Founded | 1992 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.1B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | HGV | NAMS |
|---|---|---|
| Price | $45.27 | $33.66 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 10 |
| Target Price | ★ $49.75 | $46.40 |
| AVG Volume (30 Days) | 795.1K | ★ 1.1M |
| Earning Date | 10-30-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.56 | N/A |
| Revenue | ★ $4,470,000,000.00 | $35,243,000.00 |
| Revenue This Year | $14.74 | N/A |
| Revenue Next Year | $9.35 | N/A |
| P/E Ratio | $80.26 | ★ N/A |
| Revenue Growth | ★ 5.47 | 4.91 |
| 52 Week Low | $30.59 | $14.06 |
| 52 Week High | $52.08 | $42.00 |
Technical Indicators
Market Signals| Indicator | HGV | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 65.92 | 39.02 |
| Support Level | $42.70 | $34.59 |
| Resistance Level | $44.49 | $37.41 |
| Average True Range (ATR) | 1.24 | 1.78 |
| MACD | 0.41 | -0.48 |
| Stochastic Oscillator | 77.60 | 3.42 |
Price Performance
Historical ComparisonAbout HGV Hilton Grand Vacations Inc.
Hilton Grand Vacations Inc is a timeshare company engaged in developing, marketing, selling, managing, and operating timeshare resorts, timeshare plans, and ancillary reservation services, under the Hilton Grand Vacations brand. The company operates business in the following two segments: (i) Real estate sales and financing and (ii) Resort operations and club management. The majority of the company's revenue is earned through the Real estate sales and financing segment, which generates revenue from VOI sales, and Financing.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.